CN102056611A - 用于获得不同的治疗适应症所需要的血浆孕酮水平的方法和药物组合物 - Google Patents

用于获得不同的治疗适应症所需要的血浆孕酮水平的方法和药物组合物 Download PDF

Info

Publication number
CN102056611A
CN102056611A CN2008801294325A CN200880129432A CN102056611A CN 102056611 A CN102056611 A CN 102056611A CN 2008801294325 A CN2008801294325 A CN 2008801294325A CN 200880129432 A CN200880129432 A CN 200880129432A CN 102056611 A CN102056611 A CN 102056611A
Authority
CN
China
Prior art keywords
progesterone
injectable
suspension
injection
particulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801294325A
Other languages
English (en)
Chinese (zh)
Inventor
约翰克劳德·萨瓦尔维勒伯夫
奥雷利奥·德盖维斯洛佩斯莉娜
胡安拉蒙·马丁内斯德莱昂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Posi Visionary Solutions LLP
Original Assignee
Posi Visionary Solutions LLP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Posi Visionary Solutions LLP filed Critical Posi Visionary Solutions LLP
Publication of CN102056611A publication Critical patent/CN102056611A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2008801294325A 2008-04-14 2008-04-14 用于获得不同的治疗适应症所需要的血浆孕酮水平的方法和药物组合物 Pending CN102056611A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2008/000051 WO2009128692A1 (es) 2008-04-14 2008-04-14 Método y composición farmacéutica para lograr niveles plasmáticos de progesterona requeridos para diferentes indicaciones terapéuticas

Publications (1)

Publication Number Publication Date
CN102056611A true CN102056611A (zh) 2011-05-11

Family

ID=41199287

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801294325A Pending CN102056611A (zh) 2008-04-14 2008-04-14 用于获得不同的治疗适应症所需要的血浆孕酮水平的方法和药物组合物

Country Status (8)

Country Link
US (1) US20110104289A1 (cg-RX-API-DMAC7.html)
EP (1) EP2272519A4 (cg-RX-API-DMAC7.html)
JP (1) JP2011516606A (cg-RX-API-DMAC7.html)
CN (1) CN102056611A (cg-RX-API-DMAC7.html)
BR (1) BRPI0822165A2 (cg-RX-API-DMAC7.html)
CA (1) CA2721509A1 (cg-RX-API-DMAC7.html)
IL (1) IL208723A0 (cg-RX-API-DMAC7.html)
WO (1) WO2009128692A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3080456A1 (en) * 2017-10-30 2019-05-09 Carmentix Pte. Ltd. Biomarkers of preterm birth

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663223B1 (fr) * 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
FR2663224B1 (fr) 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
JPH0474117A (ja) * 1990-07-16 1992-03-09 Kokuritsu Eisei Shikenjo 新規なマイクロスフェア
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
US6544553B1 (en) * 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
US7589082B2 (en) * 2003-06-13 2009-09-15 Skendi Finance Ltd Pharmaceutical formulation for contraception and hormone-replacement therapy

Also Published As

Publication number Publication date
EP2272519A4 (en) 2011-04-27
CA2721509A1 (en) 2009-10-22
WO2009128692A1 (es) 2009-10-22
BRPI0822165A2 (pt) 2015-06-16
IL208723A0 (en) 2010-12-30
US20110104289A1 (en) 2011-05-05
JP2011516606A (ja) 2011-05-26
EP2272519A1 (en) 2011-01-12

Similar Documents

Publication Publication Date Title
US20110104289A1 (en) Method and pharmaceutical composition for obtaining the plasmatic progesterone levels required for different therapeutic indications
AU705737B2 (en) Prolonged nerve blockage by the combination of local anesthetics and glucocorticoids
ES2799419T3 (es) Corticosteroides para el tratamiento de dolor articular
Conn, Ph. D et al. Gonadotropin-releasing hormone and its analogs
US7741273B2 (en) Drug depot implant designs
JP5666087B2 (ja) Cns関連疾患の治療のための方法及び組成物
TWI247605B (en) Combinations for the treatment of immunoinflammatory disorders
Garry et al. Evaluation of the efficacy of a bioerodible bupivacaine polymer system on antinociception and inflammatory mediator release
Nainwal Chronotherapeutics—a chronopharmaceutical approach to drug delivery in the treatment of asthma
Sonino et al. Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease
WO2014153384A1 (en) Corticosteroid formulations for the treatment of joint pain and methods of use thereof
AU771088B2 (en) Corticosteroid formulation
Venkatesan et al. Preparation and evaluation of sustained release loxoprofen loaded microspheres
US20070149493A1 (en) Sustained release hydrocortisone treatment
AU2012290683B2 (en) Corticosteroids for the treatment of joint pain
Shoupe et al. Endocrinologic effects of the antiprogesterone RU 486 in the luteal phase of normal women
Eskay et al. The effects of alcohol on selected regulatory aspects of the stress axis
US20170100411A1 (en) Corticosteroid formulations for maintaining corticosteroid synovial fluid concentrations
MX2010011296A (es) Metodo y composicion farmaceutica para lograr niveles plasmaticos de progesterona requeridos para diferentes indicaciones terapeuticas.
WO2018112408A1 (en) Fluticasone formulations and methods of use thereof
Krowicki et al. Serotonin and thyrotropin-releasing hormone do not augment their effects on gastric motility on their microinjection into the nucleus raphe obscurus of the rat.
AU2015268647B2 (en) Corticosteroids for the Treatment of Joint Pain
KR102361801B1 (ko) 발렌토닌을 함유하는 경피 치료 시스템 및 약제로서의 그것의 사용
Rojas et al. Studies on the antireproductive mechanisms of action of RU 486
HK1182956B (en) Corticosteroids for the treatment of joint pain

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110511